Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 18 Aug 2021
BeiGene and EUSA Pharma announce China NMPA approval of Qarziba (dinutuximab beta) for patients with high risk neuroblastoma
17 August 2021 - BeiGene and EUSA Pharma today announced that the China National Medical Products Administration has granted Qarziba (dinutuximab ...
Posted by Michael Wonder on 18 Aug 2021
Pharmaceutical companies should pay for raiding nature's medicine cabinet
11 August 2021 - In 2019, the pharmaceutical industry profited from US$1·2 trillion of global spending on medicines. Most of this ...
Posted by Michael Wonder on 17 Aug 2021
Tempus submits PMA application to the FDA for its xT-Onco assay
17 August 2021 - Tempus today announced the submission of a premarket approval application for its proprietary broad-panel DNA sequencing ...
Posted by Michael Wonder on 17 Aug 2021
Novartis secures new approval in China for Cosentyx (secukinumab) in paediatric psoriasis
17 August 2021 - China NMPA approval reinforces that Cosentyx (secukinumab) is safe and effective for children and adults with psoriasis. ...
Posted by Michael Wonder on 17 Aug 2021
Will Government further expand reimbursement for rare leukaemia drugs?
17 August 2021 - As the Government has gradually increased reimbursement for combination drugs treating chronic lymphocytic leukaemia, patients’ hopes ...
Posted by Michael Wonder on 17 Aug 2021
EMA validates Bristol Myers Squibb’s applications for Opdivo (nivolumab) and Yervoy (ipilimumab) and Opdivo and chemotherapy as first-line treatments for unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma
17 August 2021 - Applications based on positive results from the Phase 3 CheckMate-648 trial, in which both Opdivo-based combinations demonstrated ...
Posted by Michael Wonder on 17 Aug 2021
ICER publishes final evidence report and policy recommendations on therapies for atopic dermatitis
17 August 2021 - Given uncertainty about safety data on oral JAK inhibitors for other indications, a narrow majority of the ...
Posted by Michael Wonder on 17 Aug 2021
Agios announces FDA acceptance and priority review of new drug application for mitapivat for treatment of adults with pyruvate kinase deficiency
17 August 2021 - PDUFA date set for 17 February 2022. ...
Posted by Michael Wonder on 17 Aug 2021
FDA grants accelerated approval of Jemperli (dostarlimab-gxly) for dMMR recurrent or advanced solid tumours
17 August 2021 - Second FDA approval of PD-1 antagonist antibody under clinical development for solid tumours in collaboration with GSK. ...
Posted by Michael Wonder on 17 Aug 2021
Helius Medical Technologies announces FDA breakthrough device designation for the treatment of dynamic gait and balance deficits following a stroke
17 August 2021 - Helius Medical Technologies today announced that it has received breakthrough designation from the U.S. FDA for its ...
Posted by Michael Wonder on 17 Aug 2021
Oncopeptides' Pepaxto receives a permanent J code, clarifying reimbursement processes in hospital outpatient and physician office settings of care
16 August 2021 - Oncopeptides today announced that the Centers for Medicare and Medicaid Services has established a specific billing Level ...
Posted by Michael Wonder on 17 Aug 2021
Information Act shows racism in PHARMAC’s decision-making
17 August 2021 - Paati Māori Co-leader, Debbie Ngarewa-Packer, has received information that blatantly outlines the inequity within PHARMAC and ...
Posted by Michael Wonder on 17 Aug 2021
Final terms of reference and public consultation to the post-market review of opiate dependence treatment program medicines
17 August 2021 - The public consultation process for the post-market review of opiate dependence treatment program medicines is now ...
Posted by Michael Wonder on 17 Aug 2021
PHARMAC to fund new cardiovascular medicine with amended Special Authority criteria
17 August 2021 - Pharmac has approved funding for a new medicine with substantial health benefits for around 75,000 New ...
Posted by Michael Wonder on 16 Aug 2021
Abbott's Amplatzer Amulet device approved by FDA to treat people with atrial fibrillation at risk of stroke
16 August 2021 - Amulet is the first and only minimally invasive treatment option to offer immediate closure of the left ...